Viropro Financial Statements From 2010 to 2026

VPRO Stock  USD 0.00002  0.00  0.00%   
Viropro's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Viropro's valuation are provided below:
Market Capitalization
18.3 K
Enterprise Value Revenue
11.7546
Quarterly Revenue Growth
1.19
We have found one hundred eleven available fundamental trend indicators for Viropro, which can be analyzed and compared to other ratios and to its competition. Self-guided Investors are advised to double-check Viropro's current fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 19th of January 2026, Market Cap is likely to drop to about 1.4 M. In addition to that, Enterprise Value is likely to drop to about 1.5 M

Viropro Total Revenue

689,601

Check Viropro financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viropro's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 1 M or Total Revenue of 689.6 K, as well as many indicators such as Price To Sales Ratio of 2.37, Dividend Yield of 0.0 or PTB Ratio of 0.8. Viropro financial statements analysis is a perfect complement when working with Viropro Valuation or Volatility modules.
  
Build AI portfolio with Viropro Stock
Check out the analysis of Viropro Correlation against competitors.
To learn how to invest in Viropro Stock, please use our How to Invest in Viropro guide.

Viropro Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2.6 M2.4 MM
Slightly volatile
Other Current Liabilities17.5 K18.4 K23.7 K
Slightly volatile
Total Current Liabilities582.5 K591.4 K674.7 K
Slightly volatile
Accounts Payable365.2 K530.2 K456.2 K
Very volatile
Cash42.7 K67.8 K55.2 K
Slightly volatile
Long Term Debt388.5 K437.1 K477.1 K
Slightly volatile
Net Receivables125.5 K119.5 K100.1 K
Slightly volatile
Other Current Assets8.6 KK16.6 K
Slightly volatile
Total Liabilities712 K591.4 K710.9 K
Slightly volatile
Short and Long Term Debt258.1 K158 K209.8 K
Slightly volatile
Total Current Assets132.8 K198.8 K169.5 K
Pretty Stable
Short Term Debt258.1 K158 K209.8 K
Slightly volatile
Common Stock188.4 K360.5 K292.5 K
Pretty Stable
Property Plant Equipment69.6 K66.3 K55.6 K
Slightly volatile
Other Assets4.5 KK5.5 K
Slightly volatile
Good Will1.5 M1.7 M1.8 M
Slightly volatile

Viropro Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General AdministrativeM1.8 M1.5 M
Pretty Stable
Research Development123.1 K138.5 K151.1 K
Slightly volatile

Viropro Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock47.9 K50.4 K100.1 K
Slightly volatile
Change In Cash37.4 K35.6 K39.9 K
Slightly volatile
Other Cashflows From Financing Activities124.7 K195.5 K168.8 K
Pretty Stable
Depreciation23.5 K24.8 K65.3 K
Slightly volatile
Total Cash From Financing Activities441.8 K236.7 K303 K
Slightly volatile
Other Cashflows From Investing Activities45.3 K43.2 K44.9 K
Slightly volatile
Change To Netincome118.3 K110.7 K115.1 K
Slightly volatile
Change To Liabilities225 K214.3 K182.9 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.372.492.7296
Slightly volatile
Days Sales Outstanding38.3859.7762.2006
Very volatile
Average Payables356.2 K339.2 K351.8 K
Slightly volatile
Capex To Depreciation0.04820.05070.5925
Slightly volatile
EV To Sales2.592.733.0602
Slightly volatile
Sales General And Administrative To Revenue2.192.472.6961
Slightly volatile
Cash Per Share3.0E-43.0E-40.001
Slightly volatile
Income Quality0.520.770.6966
Slightly volatile
Intangibles To Total Assets0.60.80.8519
Pretty Stable
Current Ratio0.290.31.451
Slightly volatile
Receivables Turnover9.816.326.2016
Very volatile
Debt To Equity0.110.12050.176
Slightly volatile
Capex Per Share0.00.01.0E-4
Slightly volatile
Average Receivables1.3 K1.4 K1.6 K
Slightly volatile
Revenue Per Share0.00250.00270.0027
Slightly volatile
Interest Debt Per Share8.0E-49.0E-40.0021
Slightly volatile
Debt To Assets0.0710.07480.0976
Slightly volatile
Operating Cycle38.3859.7762.2006
Very volatile
Price Earnings To Growth Ratio0.02140.02250.2548
Slightly volatile
Company Equity Multiplier1.371.311.4146
Pretty Stable
Total Debt To Capitalization0.130.120.1339
Slightly volatile
Debt Equity Ratio0.110.12050.176
Slightly volatile
Quick Ratio0.290.31.451
Slightly volatile
Cash Ratio0.0980.10.9204
Slightly volatile
Cash Conversion Cycle38.3859.7762.2006
Very volatile
Days Of Sales Outstanding38.3859.7762.2006
Very volatile
Free Cash Flow Operating Cash Flow Ratio0.820.90.9879
Slightly volatile
Fixed Asset Turnover16.3211.3910.9528
Very volatile
Debt Ratio0.0710.07480.0976
Slightly volatile
Price Sales Ratio2.372.492.7296
Slightly volatile
Asset Turnover0.20.240.2614
Pretty Stable

Viropro Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.4 M1.4 M1.3 M
Pretty Stable
Enterprise Value1.5 M1.6 M1.4 M
Very volatile

About Viropro Financial Statements

Viropro investors utilize fundamental indicators, such as revenue or net income, to predict how Viropro Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Total Revenue656.8 K689.6 K
Sales General And Administrative To Revenue 2.47  2.19 
Ebit Per Revenue(1.57)(1.65)

Pair Trading with Viropro

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Viropro position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viropro will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Viropro could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Viropro when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Viropro - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Viropro to buy it.
The correlation of Viropro is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Viropro moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Viropro moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Viropro can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Viropro offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Viropro's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Viropro Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Viropro Stock:
Check out the analysis of Viropro Correlation against competitors.
To learn how to invest in Viropro Stock, please use our How to Invest in Viropro guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viropro. If investors know Viropro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viropro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Revenue Growth
1.19
The market value of Viropro is measured differently than its book value, which is the value of Viropro that is recorded on the company's balance sheet. Investors also form their own opinion of Viropro's value that differs from its market value or its book value, called intrinsic value, which is Viropro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viropro's market value can be influenced by many factors that don't directly affect Viropro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viropro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Viropro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viropro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.